ANVS
| Market cap | $98.46M |
|---|---|
| Enterprise value | $66.47M |
| Revenue | $0.00 |
|---|---|
| EBITDA | N/A |
| Income | -$47.53 |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E | N/A |
|---|---|
| Forward P/E | N/A |
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | N/A |
| P/FCF | N/A |
| Price/Book | -12.70 |
| Book/Share | -1.22 |
| Cash/Share | 0.90 |
| FCF yield | -35.93% |
| Volume | 22.043M / 553.624k |
|---|---|
| Relative vol. | 39.82 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | 165.71% |
| Est. EPS Q/Q | 33.33% |
| Profit margin | 0.00% |
|---|---|
| Oper. margin | N/A |
| Gross margin | N/A |
| EBIT margin | N/A |
| EBITDA margin | N/A |
| Ret. on assets | -372.37% |
|---|---|
| Ret. on equity | -1,166.77% |
| ROIC | -243.15% |
| ROCE | -1,615.00% |
| Debt/Equity | -2.32 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.60 |
| Quick ratio | 1.60 |
| Volatility | 9.74% |
|---|---|
| Beta | 1.22 |
| RSI | 80.62 |
|---|
| Insider ownership | 34.96% |
|---|---|
| Inst. ownership | 9.28% |
| Shares outst. | 8.164M |
|---|---|
| Shares float | 5.638M 69.06% |
| Short % of float | 3.02% |
| Short ratio | 8.49 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | N/A |
Tuesday, 11 October 2022
|
|
| Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease | |
Thursday, 6 October 2022
|
|
| Lab Notes: Venatorx lands federal contract that could be worth $318M; Annovis Bio receives FDA approval to proceed with trial | |
| Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease | |
Tuesday, 13 September 2022
|
|
| Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases - Yahoo Finance | |
Thursday, 28 April 2022
|
|
| Annovis Bio Announces Cooperative Research and Development Agreement with the National Institute on Aging - Yahoo Finance | |
Tuesday, 8 March 2022
|
|
| Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - Yahoo Finance | |
Friday, 28 January 2022
|
|
| Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City | |
Tuesday, 25 January 2022
|
|
| Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease | |
Friday, 7 January 2022
|
|
| Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M | |
Monday, 3 January 2022
|
|
| Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - Yahoo Finance | |
Monday, 20 December 2021
|
|
| Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders | |
Monday, 15 November 2021
|
|
| Annovis Bio Announces Transfer of Listing to the New York Stock Exchange | |
Friday, 12 November 2021
|
|
| Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - Yahoo Finance | |
Wednesday, 13 October 2021
|
|
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Annovis Bio, Cassava Sciences, The Honest Company, and Hyzon Motors and Encourages Investors to Contact the Firm - Yahoo Finance | |
Tuesday, 12 October 2021
|
|
| MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | |
| MONDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS - Yahoo Finance | |
Monday, 11 October 2021
|
|
| ANNOVIS BIO Investor Alert: Class Action Lawsuit Filed | |
| ANVS LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Annovis Bio, Inc. | |
| DEADLINE NEXT WEEK: Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS | |
Sunday, 10 October 2021
|
|
| DEADLINE APPROACHING: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ANVS - Yahoo Finance | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Maria Luisa Maccecchini President and CEO | Option 6 Feb 2023 | $7,386 |
| Maria Luisa Maccecchini President and CEO | Option 14 Jan 2022 | $4,614 |
| Michael B Hoffman Director | Option 3 Jan 2022 | $133,340 |
| Mark K. White Director | Buy 12 Oct 2021 | $137,000 |
| Claudine Bruck Director | Buy 11 Oct 2021 | $5,006 |
| Maria Luisa Maccecchini President and CEO | Buy 11 Oct 2021 | $496,980 |
| Reid Mc Carthy Director | Buy 19 Aug 2021 | $18,805 |
| Claudine Bruck Director | Buy 31 Jan 2020 | $4,800 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Mark White | |||
| Robert Whelan | |||
| Claudine Bruck | |||
| Maria Maccecchini | 2019 | ||
| Michael Hoffman (68) Chairman of the Board since 2015 | 68 | 2015 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio, Inc. was founded in 2008 and is based in Berwyn, Pennsylvania.
- Health Care > Biotechnology
- Annovis Bio, Inc., 1055 Westlakes Drive, Berwyn 19312, United States
- 610 727 3913
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $3.136968 | $5.75472 | |||
| Short term investments | |||||
| Net receivables | |||||
| Inventory | |||||
| Total current assets | $7.813295 | $10.208264 | |||
| Long term investments | |||||
| Property, plant & equipment | |||||
| Goodwill & intangible assets | |||||
| Total noncurrent assets | |||||
| Total investments | |||||
| Total assets | $7.813295 | $10.208264 | |||
| Current liabilities | |||||
| Accounts payable | $4.106832 | $1.292837 | |||
| Deferred revenue | |||||
| Short long term debt | |||||
| Total current liabilities | $4.870015 | $4.27911 | |||
| Long term debt | |||||
| Total noncurrent liabilities | $6.297308 | $13.68 | |||
| Total debt | |||||
| Total liabilities | $11.167323 | $17.95911 | |||
| Stockholders' equity | |||||
| Retained earnings | -$111.326034 | -$110.259087 | |||
| Other stockholder equity | |||||
| Total stockholder equity | -$3.354028 | -$7.750846 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.75472 | $28.377693 | ||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $10.208264 | $36.022069 | ||
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $10.208264 | $36.022069 | ||
| Current liabilities | ||||
| Accounts payable | $1.292837 | $3.961254 | ||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $4.27911 | $7.698539 | ||
| Long term debt | ||||
| Total noncurrent liabilities | $13.68 | |||
| Total debt | ||||
| Total liabilities | $17.95911 | $7.698539 | ||
| Stockholders' equity | ||||
| Retained earnings | -$110.259087 | -$54.054774 | ||
| Other stockholder equity | ||||
| Total stockholder equity | -$7.750846 | $28.32353 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | |||||
| Cost of revenue | |||||
| Gross profit | |||||
| Operating activities | |||||
| Research & development | $6.51492 | $8.904729 | |||
| Selling, general & administrative | $1.294887 | $1.537595 | |||
| Total operating expenses | $7.809807 | $10.442324 | |||
| Operating income | -$7.809807 | -$10.442324 | |||
| Income from continuing operations | |||||
| EBIT | -$1.066947 | -$22.213394 | |||
| Income tax expense | |||||
| Interest expense | |||||
| Net income | |||||
| Net income | -$1.066947 | -$22.213394 | |||
| Income (for common shares) | -$1.066947 | -$22.213394 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross profit | ||||
| Operating activities | ||||
| Research & development | $38.790603 | $16.515543 | ||
| Selling, general & administrative | $6.244408 | $8.995736 | ||
| Total operating expenses | $45.035011 | $25.511279 | ||
| Operating income | -$45.035011 | -$25.511279 | ||
| Income from continuing operations | ||||
| EBIT | -$56.204313 | -$25.328567 | ||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$56.204313 | -$25.328567 | ||
| Income (for common shares) | -$56.204313 | -$25.328567 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$1.066947 | -$22.213394 | |||
| Operating activities | |||||
| Depreciation | |||||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $0.364765 | $0.882384 | |||
| Total cash flows from operations | -$7.032752 | -$9.364976 | |||
| Investing activities | |||||
| Capital expenditures | |||||
| Investments | |||||
| Total cash flows from investing | |||||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $4.415 | $8.764754 | |||
| Net borrowings | |||||
| Total cash flows from financing | $4.415 | $8.764754 | |||
| Effect of exchange rate | |||||
| Change in cash and equivalents | -$2.617752 | -$0.600222 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$56.204313 | -$25.328567 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.628406 | $9.15252 | ||
| Total cash flows from operations | -$39.967304 | -$17.312934 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $17.344331 | $0.004613 | ||
| Net borrowings | ||||
| Total cash flows from financing | $17.344331 | $0.004613 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$22.622973 | -$17.308321 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Adage Capital Partners Gp, L.L.C |
-12.39%
|
250,000 | $2,975,000 |
| 2024 Q1 | Cannell & Spears |
Opened
|
15,000 | $178,500 |
| 2024 Q1 | Cetera Investment Advisers |
Opened
|
11,175 | $132,983 |
| 2024 Q1 | Bridgeway Capital Management |
+42.37%
|
33,600 | $399,840 |
| 2024 Q1 | Morgan Stanley |
+399.02%
|
7,156 | $85,157 |
| 2024 Q1 | State Street Corp |
+23.79%
|
29,135 | $346,707 |
| 2024 Q1 | Northern Trust Corp |
-16.46%
|
24,267 | $288,778 |
| 2024 Q1 | Tower Research Capital (trc) |
+1,036.97%
|
4,798 | $57,096 |
| 2024 Q1 | Quest Partners |
Opened
|
3,340 | $39,746 |
| 2024 Q1 | Bank Of America Corp de/ |
+68.68%
|
5,514 | $65,617 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Vanguard Group Inc | 3.17% | 258,530 | |
| Adage Capital Partners Gp, L.L.C | 3.06% | 250,000 | |
| Blackrock | 1.20% | 97,629 | |
| Geode Capital Management | 0.84% | 68,776 | |
| Independence Advisors | 0.56% | 45,598 | |
| Wescott Advisory | 0.51% | 41,607 | |
| Redmond Asset Management | 0.44% | 36,157 | |
| Sterling Investment Advisors | 0.42% | 34,374 | |
| Bridgeway Capital Management | 0.41% | 33,600 | |
| Modera Wealth Management | 0.37% | 30,513 |
Sign up